Caribou Biosciences, Inc. (CRBU)
Nasdaq · Healthcare · Biotechnology
$1.19−2.46%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $128M
- 52-week range
- $1.17 – $3.54
- 52-week change
- −47.86%
- EPS (trailing)
- −$1.08
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $11.2M (+11.66%)
- Net income
- −$148M
- Operating margin
- −1329.3%
- Diluted EPS
- −$1.59
- Free cash flow
- −$112M
From the company’s annual report on SEC EDGAR.
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Headquarters: Berkeley, United States · 97 employees · cariboubio.com